Skip to main content

Omega Therapeutics, Inc. (OMGA)

NASDAQ: OMGA · Delayed Price · USD
18.80 -1.11 (-5.58%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap876.54M
Revenue (ttm)n/a
Net Income (ttm)-37.52M
Shares Out46.62M
EPS (ttm)-0.80
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close19.91
Day's Range18.76 - 21.14
52-Week Range15.50 - 24.29
Price Target29.50 (+56.9%)
Est. Earnings DateNov 15, 2021

About OMGA

At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We rationally design and engineer modular, programmable mRNA-encoded epigenetic medicines, which we call Omega Epigenomic Controllers, or OECs, to target DNA-se...

IPO DateJul 30, 2021
CEOMahesh Karande
Stock ExchangeNASDAQ
Ticker SymbolOMGA
Full Company Profile

Financial Performance

Financial Statements


Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives

CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therape...

1 week ago - PRNewsWire

Tuesday Afternoon Analyst Upgrades and Downgrades: Palo Alto Networks, Victoria's Secret and More

With the trading day more than halfway over, the broad markets were seeing another round of gains on Tuesday.

4 weeks ago - 24/7 Wall Street

Omega Therapeutics Kicks Start Trading On NASDAQ

On the heels of a $126 million crossover round in March, Flagship Pioneering-backed Omega Therapeutics Inc (NASDAQ: OMGA) has priced a $125.8 million IPO to take its "epigenomic controllers" into the cl...

1 month ago - Benzinga

Omega Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harne...

1 month ago - PRNewsWire

Omega Therapeutics IPO Registration Document (S-1)

Omega Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC